Möckel Martin, Searle Julia, Baberg Henning Thomas, Dirschedl Peter, Levenson Benny, Malzahn Jürgen, Mansky Thomas, Günster Christian, Jeschke Elke
Division of Emergency Medicine and Chest Pain Units, Department of Cardiology , Campus Virchow Klinikum and Campus Charité Mitte, Charité-Universitätsmedizin Berlin , Berlin , Germany.
Department of Cardiology and Nephrology , Helios Klinikum, Berlin-Buch , Berlin , Germany.
Open Heart. 2016 Oct 3;3(2):e000464. doi: 10.1136/openhrt-2016-000464. eCollection 2016.
We aimed to analyse the short-term and long-term outcome of patients with end-stage renal disease (ESRD) undergoing percutaneous intervention (PCI) as compared to coronary artery bypass surgery (CABG) to evaluate the optimal coronary revascularisation strategy.
Retrospective analysis of routine statutory health insurance data between 2010 and 2012.
Primary outcome was adjusted all-cause mortality after 30 days and major adverse cardiovascular and cerebrovascular events at 1 year. Secondary outcomes were repeat revascularisation at 30 days and 1 year and bleeding events within 7 days.
The total number of cases was n=4123 (PCI; n=3417), median age was 71 (IQR 62-77), 30.4% were women. The adjusted OR for death within 30 days was 0.59 (95% CI 0.43 to 0.81) for patients undergoing PCI versus CABG. At 1 year, the adjusted OR for major adverse cardiac and cerebrovascular events (MACCE) was 1.58 (1.32 to 1.89) for PCI versus CABG and 1.47 (1.23 to 1.75) for all-cause death. In the subgroup of patients with acute myocardial infarction (AMI), adjusted all-cause mortality at 30 days did not differ significantly between both groups (OR 0.75 (0.47 to 1.20)), whereas in patients without AMI the OR for 30-day mortality was 0.44 (0.28 to 0.68) for PCI versus CABG. At 1 year, the adjusted OR for MACCE in patients with AMI was 1.40 (1.06 to 1.85) for PCI versus CABG and 1.47 (1.08 to 1.99) for mortality.
In this cohort of unselected patients with ESRD undergoing revascularisation, the 1-year outcome was better for CABG in patients with and without AMI. The 30-day mortality was higher in non-AMI patients with CABG reflecting an early hazard with surgery. In cases where the patient's characteristics and risk profile make it difficult to decide on a revascularisation strategy, CABG could be the preferred option.
我们旨在分析终末期肾病(ESRD)患者接受经皮介入治疗(PCI)与冠状动脉旁路移植术(CABG)相比的短期和长期预后,以评估最佳的冠状动脉血运重建策略。
对2010年至2012年常规法定医疗保险数据进行回顾性分析。
主要结局为30天时调整后的全因死亡率和1年时主要不良心血管和脑血管事件。次要结局为30天和1年时的再次血运重建以及7天内的出血事件。
病例总数为n = 4123(PCI;n = 3417),中位年龄为71岁(四分位间距62 - 77岁),女性占30.4%。接受PCI与CABG的患者在30天内死亡的调整后比值比为0.59(95%可信区间0.43至0.81)。在1年时,接受PCI与CABG的患者发生主要不良心脏和脑血管事件(MACCE)的调整后比值比为1.58(1.32至1.89),全因死亡的调整后比值比为1.47(1.23至1.75)。在急性心肌梗死(AMI)患者亚组中,两组在30天时的调整后全因死亡率无显著差异(比值比0.75(0.47至1.20)),而在无AMI的患者中,PCI与CABG相比30天死亡率的比值比为0.44(0.28至0.68)。在1年时,AMI患者接受PCI与CABG相比MACCE的调整后比值比为1.40(1.06至1.85),死亡率的调整后比值比为1.47(1.08至1.99)。
在这组接受血运重建的未选择的ESRD患者中,无论有无AMI,CABG的1年结局更好。非AMI患者接受CABG时30天死亡率较高,反映出手术的早期风险。在患者特征和风险状况难以决定血运重建策略的情况下,CABG可能是首选方案。